Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech... Show more
Industry PharmaceuticalsMajor
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BIAUX | 24.25 | -1.05 | -4.15% |
| Brown Advisory Small-Cap Fdmtl Val Inv | |||
| MGKAX | 10.91 | -0.51 | -4.47% |
| Morgan Stanley Global Permanence A | |||
| JLVRX | 18.05 | -1.08 | -5.65% |
| JPMorgan Large Cap Value R5 | |||
| SWLSX | 29.26 | -1.89 | -6.07% |
| Schwab Large-Cap Growth | |||
| NQGIX | 33.21 | -2.16 | -6.11% |
| Nuveen Global Equity Income I | |||
A.I.dvisor tells us that CMOPF and GSK have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CMOPF and GSK's prices will move in lockstep.
| Ticker / NAME | Correlation To CMOPF | 1D Price Change % | ||
|---|---|---|---|---|
| CMOPF | 100% | N/A | ||
| GSK - CMOPF | 22% Poorly correlated | -6.36% | ||
| NVS - CMOPF | 21% Poorly correlated | -5.71% | ||
| CHGCY - CMOPF | 7% Poorly correlated | +0.45% | ||
| DSNKY - CMOPF | 5% Poorly correlated | -1.80% | ||
| CSPCY - CMOPF | 4% Poorly correlated | -6.14% | ||
More | ||||